Advocacy intelligence hub — real-time data for patient organizations
Jakkrit Juhong — NA
Sam Chun Dang Pharm. Co. Ltd. — PHASE2
Harrow Inc — PHASE4
Inje University — NA
Bayer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine — NA
Annexin Pharmaceuticals AB — PHASE2
MediBeacon — EARLY_PHASE1
SciNeuro — PHASE2
Tanta University — EARLY_PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs2
Eylea
Regeneron Pharmaceuticals, Inc.
Ozurdex
Allergan
Eylea
(aflibercept)Orphan drugstandardRegeneron Pharmaceuticals, Inc.
Vascular Endothelial Growth Factor Inhibitor [EPC]
12.1 Mechanism of Action Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic...
Ozurdex
(dexamethasone intravitreal implant)Orphan drugstandardAllergan
Corticosteroid [EPC]
12.1 Mechanism of Action Dexamethasone, a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines result...
Agnès GLACET-BERNARD, MD
Centre Hospitalier Intercommunal Créteil
Pablo Velazquez-Martin, MD
Kodiak Sciences Inc
Thomas Ciulla, MD, M.D
Clearside Biomedical, Inc.
📍 CARMEL, IN
Lawrence A. Yannuzzi, MD, MD
Manhattan Eye, Ear & Throat Hospital
📍 NEW YORK, NY
Allen Chiang, MD, DO
Mid Atlantic Retina
📍 WASHINGTON, DC
Xiaorong Li, MD, DOM
Tianjin Medical University Eye Hospital
📍 ALBUQUERQUE, NM